Assessing the correlation between the benign prostatic hyperplasia Bother Impact Index and International Prostate Symptom Score after transurethral resection of the prostate
Accepted: 2 May 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Improvements in Lower Urinary Tract Symptoms (LUTS) and Quality of Life (QoL) are usually the key reasons men seek surgical options for their management. Transurethral Resection of the Prostate (TURP) is an effective surgical option for these patients, and it is increasingly being employed in the management of Benign Prostatic Hyperplasia (BPH) patients. The aim of this study was to evaluate the effect of TURP on the Bother Impact Index (BII) score and International Prostate Symptom Score (IPSS) and assess the correlation between these two parameters three months after TURP. This was a prospective study of 194 men who had TURP between February 2018 and October 2019. On clinical evaluation, all the patients included in the study had moderate to severe LUTS attributable to BPH. Preoperatively, detailed histories were taken of each patient, and the IPSS questionnaire was administered. The mean age of the participants was 66.28 years (Standard Deviation, SD=8.19). The modal age group was the sixth decade. The mean BII score of the patients was 5.73 (SD=0.45), and the mean IPPS of the patients was 25.85 (SD=5.07). The mean BII score 3 months post-TURP was 1.44 (SD±0.91), while the mean IPSS 3 months post-TURP was 2.75 (SD±1.33). There was a strong positive and statistically significant correlation between BII score and IPSS at 3 months post-TURP (r=+0.770, p<0.001).
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.